Structural Insights into Ceftobiprole Inhibition of Pseudomonas aeruginosa Penicillin-Binding Protein 3.
Vijay KumarChristie TangChristopher R BethelKrisztina M Papp-WallaceJacob WyattEric DesarbreRobert A BonomoFocco van den AkkerPublished in: Antimicrobial agents and chemotherapy (2020)
Ceftobiprole is an advanced-generation broad-spectrum cephalosporin antibiotic with potent and rapid bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, as well as susceptible Gram-negative pathogens, including Pseudomonas sp. pathogens. In the case of Pseudomonas aeruginosa, ceftobiprole acts by inhibiting P. aeruginosa penicillin-binding protein 3 (PBP3). Structural studies were pursued to elucidate the molecular details of this PBP inhibition. The crystal structure of the His-tagged PBP3-ceftobiprole complex revealed a covalent bond between the ligand and the catalytic residue S294. Ceftobiprole binding leads to large active site changes near binding sites for the pyrrolidinone and pyrrolidine rings. The S528 to L536 region adopts a conformation previously not observed in PBP3, including partial unwinding of the α11 helix. These molecular insights can lead to a deeper understanding of β-lactam-PBP interactions that result in major changes in protein structure, as well as suggesting how to fine-tune current inhibitors and to develop novel inhibitors of this PBP.
Keyphrases
- gram negative
- binding protein
- multidrug resistant
- pseudomonas aeruginosa
- methicillin resistant staphylococcus aureus
- acinetobacter baumannii
- cystic fibrosis
- drug resistant
- biofilm formation
- staphylococcus aureus
- air pollution
- signaling pathway
- escherichia coli
- amino acid
- anti inflammatory
- transcription factor
- candida albicans